News

Boston Therapeutics, Inc. Submits SugarDown™ to the US Food and Drug Administration

Boston Therapeutics, Inc. Submits SugarDown™ to the US Food and Drug Administration

Download PDF

SUGARDOWN™: A breakthrough in Complex Carbohydrate Chemistry Produces a Novel Dietary Supplement that Supports Glycemic and Digestive Health

MANCHESTER, N.H.--(BUSINESS WIRE)--Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.

 “SUGARDOWN™ submission to the FDA for structure and function claims as a dietary supplement complies with United State code 21 CFR 101.93. This establishes the basis for our scientific rationale and the clinical benefits of SUGARDOWN™ such as supporting healthy glycemic index, increased fiber intake, and improved overall digestive health” said Ken Tassey, President, Chief Executive Officer and co-founder of Boston Therapeutics, Inc. www.bostonti.com . “SUGARDOWN™ is a first-in-class dietary supplement that offers convenient management of high glycemic index foods. This submission provides Boston Therapeutics with scientific and clinical advantages and mass-market appeal”, added Ken Tassey.

“Collaboration between Boston Therapeutics, Inc. carbohydrate scientists and our experienced business and marketing teams has led to fast track development by a Good Manufacturing Practice (GMP) facility and early marketing of SUGARDOWN™. Under the management of Ken Tassey, and in collaboration with the GMP facility, Boston Therapeutics was able to fulfill an unmet market need. Our Marketing and Information Technology teams have set up state-of-the-art distribution and information centers for customer support”, said Dr. David Platt, Chairman and co-founder of Boston Therapeutics Inc.

Ken Tassey is President and Chief Executive Officer of Boston Therapeutics Inc since its inception in June 2009. Mr. Tassey was previously a consultant for various finance and marketing projects with experience in operations, banking, marketing and sales.

Dr. David Platt developed SUGARDOWN™ out of an understanding of the benefits of complex carbohydrates to human health. Dr. Platt co-authored two books about carbohydrate recognition entitled Carbohydrate Drug Designand Galectins.

About Glycemic Index

The glycemic index is a measure of the influence of carbohydrates on blood glucose levels.Carbohydrates with a high glycemic index are those which break down quickly during digestion releasing glucose rapidly into the blood; carbohydrates that digest more slowly, releasing glucose gradually into the blood, have a low glycemic index.

About SugarDown™

SugarDown™, a novel dietary supplement, is a user-ready chewable tablet eaten before meals that moderates the body’s absorption of glucose formed during digestion. SugarDown™ works in the gastrointestinal tract, while most anti-hyperglycemic drugs and dietary supplements for diabetics address blood glucose already present in the blood. SUGARDOWN™ may provide benefit to pre-diabetic and diabetic patients in managing their glycemic health.

Boston Therapeutics Inc.

Boston therapeutics Inc. is the leader in the field of complex carbohydrate products and is engaged in the discovery, development, and commercialization of dietary supplements for human health. www.bostonti.com

SUGARDOWN™ is a registered trademark of Boston Therapeutics, Inc.